Trials / Completed
CompletedNCT01987232
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer
Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive-stage Small-cell Lung Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib given in combination with carboplatin and etoposide as initial therapy for patients with extensive-stage small-cell lung cancer (ES SCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Carfilzomib | Administered by intravenous infusion. |
| DRUG | Carboplatin | Administered by intravenous infusion. |
| DRUG | Etoposide | Administered by intravenous infusion. |
Timeline
- Start date
- 2013-11-05
- Primary completion
- 2016-08-01
- Completion
- 2017-05-04
- First posted
- 2013-11-19
- Last updated
- 2017-08-28
- Results posted
- 2017-08-28
Locations
17 sites across 3 countries: United States, Canada, Russia
Source: ClinicalTrials.gov record NCT01987232. Inclusion in this directory is not an endorsement.